Figure 3.
Cumulative PFS of apatinib-treated patients in different sub-group. (A) HR status (P=0.001); (B) Radiation therapy after surgery in chest wall (P=0.041); (C) Lymph node metastasis after surgery (P=0.112); (D) Site and number of metastasis (P=0.258). PFS, progression-free survival; HR, hormonal receptor; IV, primary metastasis.